6533b832fe1ef96bd129af18
RESEARCH PRODUCT
Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
I. PierantonelliDebora Maria GiordanoLuca ValentiVito Di MarcoMassimiliano RuscicaCalogero CammàChiara RychlickiGianluca Svegliati BaroniMarica MeroniMarco MaggioniSilvia FargionSalvatore PettaAntonio CraxìNicola FerriRosaria Maria PipitoneAnna Ludovica FracanzaniStefania GrimaudoPaola DongiovanniDaniela Cabibisubject
Liver CirrhosisMale0301 basic medicineEndocrinology Diabetes and MetabolismClinical BiochemistrySeverity of Illness IndexBiochemistryGastroenterologyMiceEndocrinologyNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseaseOdds RatioProspective StudiesCarbon Tetrachloridemedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionHep G2 CellsMiddle AgedFNDC5LiverLiver biopsyFemaleAdultmedicine.medical_specialtyIn Vitro TechniquesDiet High-FatReal-Time Polymerase Chain ReactionPolymorphism Single Nucleotide03 medical and health sciencesDiabetes mellitusInternal medicineMyokineHepatic Stellate CellsmedicineAnimalsHumansFNDC5 IRISIN NAFLDGenetic Predisposition to Diseasebusiness.industryBiochemistry (medical)medicine.diseasedigestive system diseasesFibronectins030104 developmental biologyEndocrinologyCase-Control StudiesHepatic stellate cellSteatosisbusinessdescription
Context Contrasting data have been reported on the role of irisin, a novel myokine encoded by the fibronectin type III domain-containing protein 5 (FNDC5) gene, in nonalcoholic fatty liver disease (NAFLD) pathogenesis. We tested in patients with suspected nonalcoholic steatohepatitis (NASH) the association of FNDC5 variants, hepatic expression, and circulating irisin with liver damage (F2 to F4 fibrosis as main outcome). We also investigated whether irisin modulates hepatocellular fat accumulation and stellate cell activation in experimental models. Methods We considered 593 consecutive patients who underwent liver biopsy for suspected NASH and 192 patients with normal liver enzymes and without steatosis. FNDC5 rs3480 and rs726344 genotypes were assessed by 5' nuclease assays. Hepatic irisin expression was evaluated in mice fed a high-fat diet or treated with CCl4. The effect of irisin was evaluated in fat-laden HepG2 hepatocytes and in hepatic stellate cells (HSCs). Results In patients at risk for NASH [odds ratio (OR) = 0.64, 95% confidence interval (CI), 0.47 to 0.87; P = 0.005], and more so in the high-risk subgroup of those with impaired fasting glucose/diabetes (OR = 0.44, 95% CI, 0.26 to 0.74; P = 0.002), the rs3480 A>G variant was independently associated with protection from F2 to F4 fibrosis. Irisin is expressed in human activated HSC, where it mediated fibrogenic actions and collagen synthesis, and is overexpressed in NAFLD patients with F2 to F4 fibrosis and CCl4-treated mice. However, Irisin does not affect fat accumulation in HepG2 and is not induced by high-fat-diet-inducing NAFLD. Conclusions The FNDC5 rs3480 variant is associated with protection from clinically significant fibrosis in patients with NAFLD, while irisin expression is correlated with the severity of NAFLD and may be involved in extracellular matrix deposition. These data suggest that irisin is involved in regulation of hepatic fibrogenesis.
year | journal | country | edition | language |
---|---|---|---|---|
2017-01-01 | The Journal of Clinical Endocrinology & Metabolism |